The EU\u2019s policy priorities are a once-in-a-generation change to the regulatory framework that can offer the industrial biotech and healthcare sectors an opportunity to set a direction for the next decades and become \u201ca powerhouse for innovation\u201d, says the newly appointed chairman of EuropaBio.<\/p>\n\n\n\n
In an interview with EURACTIV, the new boss of Europe\u2019s largest biotech association, Andrew Topen, spoke about the impact on the bioindustry sector of a number of flagship policy initiatives recently put forward by a \u2018very active\u2019 EU executive.<\/p>\n\n\n\n
\u201cWe have a unique opportunity with all of these policy proposals to really become a powerhouse for innovation in the future,\u201d he said.<\/p>\n\n\n\n
He referred to several of the EU\u2019s policy priorities, ranging from the industrial strategy to the environmental ambition in the Green Deal, not to mention the pharmaceutical strategy and the new approach on digital.<\/p>\n\n\n\n
\u201cWe are working very closely with all the stakeholders to ensure that our industry\u2019s interests are understood,\u201d he stressed, adding that his association wants to ensure a robust regulatory framework that can actually be a catalyst for growth.<\/p>\n\n\n\n